Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: DNA Repair (Amst). 2020 Mar 7;89:102837. doi: 10.1016/j.dnarep.2020.102837

Figure 5. Synthetic lethality between the TDP1 and nuclease pathways in human cancers.

Figure 5.

PARP1 form a complex with TDP1, which promotes the recruitment of TDP1 to the TOP1-DPC and activates the TDP1 pathway (green arrow). PARP1 also PARylates TOP1, TDP1 and itself (autoPARylation) (brown arrows). Inactivation of the TDP1 pathway with PARP inhibitors renders ERCC1- or MRE11-deficient cells to TOP1 inhibitors.